NCT04847453

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2022-08-03Est. Completion: 2028-06-30

Enrollment target: 24 participants

Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Boston Medical Center, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Montefiore Medical Center-Einstein Campus, The Bronx, New York, United States
Montefiore Medical Center-Weiler Hospital, The Bronx, New York, United States
Montefiore Medical Center - Moses Campus, The Bronx, New York, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
University of Texas at Austin, Austin, Texas, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Mild Cognitive ImpairmentAlzheimer DiseaseDementia

The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study desig…

Birmingham, United StatesCompleted Jul 31, 2027

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for…

Duarte, United StatesEst. completion Apr 19, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.